455 related articles for article (PubMed ID: 21274504)
21. Histone Deacetylase Inhibitor Trichostatin A Ameliorated Endotoxin-Induced Neuroinflammation and Cognitive Dysfunction.
Hsing CH; Hung SK; Chen YC; Wei TS; Sun DP; Wang JJ; Yeh CH
Mediators Inflamm; 2015; 2015():163140. PubMed ID: 26273133
[TBL] [Abstract][Full Text] [Related]
22. Anti-Inflammatory Effects of Spirulina platensis Extract via the Modulation of Histone Deacetylases.
Pham TX; Park YK; Lee JY
Nutrients; 2016 Jun; 8(6):. PubMed ID: 27338466
[TBL] [Abstract][Full Text] [Related]
23. HDAC inhibitors: modulating leukocyte differentiation, survival, proliferation and inflammation.
Sweet MJ; Shakespear MR; Kamal NA; Fairlie DP
Immunol Cell Biol; 2012 Jan; 90(1):14-22. PubMed ID: 22024621
[TBL] [Abstract][Full Text] [Related]
24. Histone Deacetylases (HDACs): Evolution, Specificity, Role in Transcriptional Complexes, and Pharmacological Actionability.
Milazzo G; Mercatelli D; Di Muzio G; Triboli L; De Rosa P; Perini G; Giorgi FM
Genes (Basel); 2020 May; 11(5):. PubMed ID: 32429325
[TBL] [Abstract][Full Text] [Related]
25. Small molecule inhibitors of histone acetyltransferases and deacetylases are potential drugs for inflammatory diseases.
Dekker FJ; van den Bosch T; Martin NI
Drug Discov Today; 2014 May; 19(5):654-60. PubMed ID: 24269836
[TBL] [Abstract][Full Text] [Related]
26. HDAC inhibitor therapy in autoimmunity and transplantation.
Hancock WW; Akimova T; Beier UH; Liu Y; Wang L
Ann Rheum Dis; 2012 Apr; 71 Suppl 2():i46-54. PubMed ID: 22460138
[TBL] [Abstract][Full Text] [Related]
27. Targeting histone deacetylases for the treatment of disease.
Lawless MW; Norris S; O'Byrne KJ; Gray SG
J Cell Mol Med; 2009 May; 13(5):826-52. PubMed ID: 19175682
[TBL] [Abstract][Full Text] [Related]
28. Class 1-Selective Histone Deacetylase (HDAC) Inhibitors Enhance HIV Latency Reversal while Preserving the Activity of HDAC Isoforms Necessary for Maximal HIV Gene Expression.
Zaikos TD; Painter MM; Sebastian Kettinger NT; Terry VH; Collins KL
J Virol; 2018 Mar; 92(6):. PubMed ID: 29298886
[TBL] [Abstract][Full Text] [Related]
29. Histone deacetylase-2 is a key regulator of diabetes- and transforming growth factor-beta1-induced renal injury.
Noh H; Oh EY; Seo JY; Yu MR; Kim YO; Ha H; Lee HB
Am J Physiol Renal Physiol; 2009 Sep; 297(3):F729-39. PubMed ID: 19553350
[TBL] [Abstract][Full Text] [Related]
30. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
31. Using Histone Deacetylase Inhibitors to Analyze the Relevance of HDACs for Translation.
Hutt DM; Roth DM; Marchal C; Bouchecareilh M
Methods Mol Biol; 2017; 1510():77-91. PubMed ID: 27761814
[TBL] [Abstract][Full Text] [Related]
32. Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats.
Lundh M; Galbo T; Poulsen SS; Mandrup-Poulsen T
Diabetes Obes Metab; 2015 Jul; 17(7):703-7. PubMed ID: 25846481
[TBL] [Abstract][Full Text] [Related]
33. Histone deacetylase inhibitors interfere with angiogenesis by decreasing endothelial VEGFR-2 protein half-life in part via a VE-cadherin-dependent mechanism.
Hrgovic I; Doll M; Pinter A; Kaufmann R; Kippenberger S; Meissner M
Exp Dermatol; 2017 Feb; 26(2):194-201. PubMed ID: 27487811
[TBL] [Abstract][Full Text] [Related]
34. Effects of novel HDAC inhibitors on urothelial carcinoma cells.
Kaletsch A; Pinkerneil M; Hoffmann MJ; Jaguva Vasudevan AA; Wang C; Hansen FK; Wiek C; Hanenberg H; Gertzen C; Gohlke H; Kassack MU; Kurz T; Schulz WA; Niegisch G
Clin Epigenetics; 2018 Jul; 10(1):100. PubMed ID: 30064501
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Histone Deacetylases Permits Lipopolysaccharide-Mediated Secretion of Bioactive IL-1β via a Caspase-1-Independent Mechanism.
Stammler D; Eigenbrod T; Menz S; Frick JS; Sweet MJ; Shakespear MR; Jantsch J; Siegert I; Wölfle S; Langer JD; Oehme I; Schaefer L; Fischer A; Knievel J; Heeg K; Dalpke AH; Bode KA
J Immunol; 2015 Dec; 195(11):5421-31. PubMed ID: 26519528
[TBL] [Abstract][Full Text] [Related]
36. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
37. Histone/protein deacetylases and T-cell immune responses.
Akimova T; Beier UH; Liu Y; Wang L; Hancock WW
Blood; 2012 Mar; 119(11):2443-51. PubMed ID: 22246031
[TBL] [Abstract][Full Text] [Related]
38. The inhibitory effects of class I histone deacetylases on hippocampal neuroinflammatory regulation in aging mice with postoperative cognitive dysfunction.
Yang CX; Bao F; Zhong J; Zhang L; Deng LB; Sha Q; Jiang H
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(19):10194-10202. PubMed ID: 33090427
[TBL] [Abstract][Full Text] [Related]
39. Natural Agents-Mediated Targeting of Histone Deacetylases.
Farooqi AA; Naqvi SK; Perk AA; Yanar O; Tabassum S; Ahmad MS; Mansoor Q; Ashry MS; Ismail M; Naoum GE; Arafat WO
Arch Immunol Ther Exp (Warsz); 2018 Feb; 66(1):31-44. PubMed ID: 28852775
[TBL] [Abstract][Full Text] [Related]
40. Developing histone deacetylase inhibitors in the therapeutic armamentarium of pancreatic adenocarcinoma.
Zafar SF; Nagaraju GP; El-Rayes B
Expert Opin Ther Targets; 2012 Jul; 16(7):707-18. PubMed ID: 22621256
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
